CBIH Plans Expanded Research Into Endocannabinoid Science and Personalized Medicine

By Public Technologies
  • Cannabis Bioscience International Holdings plans to expand research linking endocannabinoid biology with precision medicine to develop intellectual property with potential biomedical applications.
  • Planned studies will investigate cannabinoid interactions with cellular pathways involved in complex diseases, supporting potentially patentable technologies.
  • Anticipating proposed federal marijuana rescheduling from Schedule I to Schedule III, it intends to explore research partnerships and licensing agreements.
  • These initiatives target future commercialization through medical, pharmaceutical and biotechnology organizations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabis Bioscience International Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610190700NEWSFILECNPR____20261019_319667_1) on October 19, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk